RU2010113968A - Применение пептида в качестве терапевтического средства - Google Patents
Применение пептида в качестве терапевтического средства Download PDFInfo
- Publication number
- RU2010113968A RU2010113968A RU2010113968/15A RU2010113968A RU2010113968A RU 2010113968 A RU2010113968 A RU 2010113968A RU 2010113968/15 A RU2010113968/15 A RU 2010113968/15A RU 2010113968 A RU2010113968 A RU 2010113968A RU 2010113968 A RU2010113968 A RU 2010113968A
- Authority
- RU
- Russia
- Prior art keywords
- infection
- diseases
- disease
- infections
- entamoeba
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 8
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 claims abstract 28
- 208000035473 Communicable disease Diseases 0.000 claims abstract 8
- 230000009545 invasion Effects 0.000 claims abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 7
- 206010061217 Infestation Diseases 0.000 claims abstract 5
- 201000010099 disease Diseases 0.000 claims abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 5
- 208000004881 Amebiasis Diseases 0.000 claims abstract 4
- 206010001980 Amoebiasis Diseases 0.000 claims abstract 4
- 201000006082 Chickenpox Diseases 0.000 claims abstract 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims abstract 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims abstract 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims abstract 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims abstract 4
- 208000008953 Cryptosporidiosis Diseases 0.000 claims abstract 4
- 201000000077 Cysticercosis Diseases 0.000 claims abstract 4
- 206010046980 Varicella Diseases 0.000 claims abstract 4
- 241000700605 Viruses Species 0.000 claims abstract 4
- 201000008680 babesiosis Diseases 0.000 claims abstract 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 3
- 208000001490 Dengue Diseases 0.000 claims abstract 3
- 206010012310 Dengue fever Diseases 0.000 claims abstract 3
- 206010016654 Fibrosis Diseases 0.000 claims abstract 3
- 208000019693 Lung disease Diseases 0.000 claims abstract 3
- 210000004204 blood vessel Anatomy 0.000 claims abstract 3
- 201000011510 cancer Diseases 0.000 claims abstract 3
- 201000002641 cyclosporiasis Diseases 0.000 claims abstract 3
- 208000025729 dengue disease Diseases 0.000 claims abstract 3
- 230000004761 fibrosis Effects 0.000 claims abstract 3
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 3
- 208000030159 metabolic disease Diseases 0.000 claims abstract 3
- 230000004770 neurodegeneration Effects 0.000 claims abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 3
- 230000002265 prevention Effects 0.000 claims abstract 3
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 claims abstract 3
- 206010001935 American trypanosomiasis Diseases 0.000 claims abstract 2
- 241000243791 Angiostrongylus Species 0.000 claims abstract 2
- 206010003964 Babesia infections Diseases 0.000 claims abstract 2
- 241000193738 Bacillus anthracis Species 0.000 claims abstract 2
- 208000005740 Blastocystis Infections Diseases 0.000 claims abstract 2
- 206010005098 Blastomycosis Diseases 0.000 claims abstract 2
- 208000003508 Botulism Diseases 0.000 claims abstract 2
- 206010006500 Brucellosis Diseases 0.000 claims abstract 2
- 241000253350 Capillaria Species 0.000 claims abstract 2
- 208000024699 Chagas disease Diseases 0.000 claims abstract 2
- 206010061041 Chlamydial infection Diseases 0.000 claims abstract 2
- 208000035086 Chlamydophila Infections Diseases 0.000 claims abstract 2
- 206010008631 Cholera Diseases 0.000 claims abstract 2
- 241001327942 Clonorchis Species 0.000 claims abstract 2
- 241000223205 Coccidioides immitis Species 0.000 claims abstract 2
- 201000007336 Cryptococcosis Diseases 0.000 claims abstract 2
- 241000221204 Cryptococcus neoformans Species 0.000 claims abstract 2
- 206010011502 Cryptosporidiosis infection Diseases 0.000 claims abstract 2
- 241000256054 Culex <genus> Species 0.000 claims abstract 2
- 206010012735 Diarrhoea Diseases 0.000 claims abstract 2
- 206010014096 Echinococciasis Diseases 0.000 claims abstract 2
- 208000009366 Echinococcosis Diseases 0.000 claims abstract 2
- 241000224431 Entamoeba Species 0.000 claims abstract 2
- 241000146407 Entamoeba coli Species 0.000 claims abstract 2
- 241000204733 Entamoeba dispar Species 0.000 claims abstract 2
- 241000146401 Entamoeba hartmanni Species 0.000 claims abstract 2
- 241000146402 Entamoeba polecki Species 0.000 claims abstract 2
- 208000010489 Entamoebiasis Diseases 0.000 claims abstract 2
- 241000282326 Felis catus Species 0.000 claims abstract 2
- 206010061192 Haemorrhagic fever Diseases 0.000 claims abstract 2
- 241000244206 Nematoda Species 0.000 claims abstract 2
- 208000007316 Neurocysticercosis Diseases 0.000 claims abstract 2
- 241000223109 Trypanosoma cruzi Species 0.000 claims abstract 2
- 241000710886 West Nile virus Species 0.000 claims abstract 2
- 230000001580 bacterial effect Effects 0.000 claims abstract 2
- 208000007456 balantidiasis Diseases 0.000 claims abstract 2
- 201000003486 coccidioidomycosis Diseases 0.000 claims abstract 2
- 206010014599 encephalitis Diseases 0.000 claims abstract 2
- 230000002538 fungal effect Effects 0.000 claims abstract 2
- 150000004677 hydrates Chemical class 0.000 claims abstract 2
- 230000001617 migratory effect Effects 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 208000004441 taeniasis Diseases 0.000 claims abstract 2
- 230000003612 virological effect Effects 0.000 claims abstract 2
- 208000028454 lice infestation Diseases 0.000 claims 5
- 241000243985 Onchocerca volvulus Species 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 206010023076 Isosporiasis Diseases 0.000 claims 3
- 241000517307 Pediculus humanus Species 0.000 claims 3
- 241000242722 Cestoda Species 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 206010024229 Leprosy Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 210000003608 fece Anatomy 0.000 claims 2
- 210000004251 human milk Anatomy 0.000 claims 2
- 235000020256 human milk Nutrition 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 208000003177 ocular onchocerciasis Diseases 0.000 claims 2
- 208000002042 onchocerciasis Diseases 0.000 claims 2
- 208000000230 African Trypanosomiasis Diseases 0.000 claims 1
- 241000224489 Amoeba Species 0.000 claims 1
- 241000244203 Caenorhabditis elegans Species 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 208000003495 Coccidiosis Diseases 0.000 claims 1
- 206010011409 Cross infection Diseases 0.000 claims 1
- 241000935794 Dipylidium Species 0.000 claims 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 1
- 241000498255 Enterobius vermicularis Species 0.000 claims 1
- 206010014909 Enterovirus infection Diseases 0.000 claims 1
- 206010061126 Escherichia infection Diseases 0.000 claims 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 1
- 206010017543 Fungal skin infection Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 206010019143 Hantavirus pulmonary infection Diseases 0.000 claims 1
- 206010019375 Helicobacter infections Diseases 0.000 claims 1
- 208000025164 Hendra virus infection Diseases 0.000 claims 1
- 208000000464 Henipavirus Infections Diseases 0.000 claims 1
- 206010020429 Human ehrlichiosis Diseases 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 206010023927 Lassa fever Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 208000000932 Marburg Virus Disease Diseases 0.000 claims 1
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010056970 Naegleria infection Diseases 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 241000517324 Pediculidae Species 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 241001674048 Phthiraptera Species 0.000 claims 1
- 206010035148 Plague Diseases 0.000 claims 1
- 241000517305 Pthiridae Species 0.000 claims 1
- 206010037688 Q fever Diseases 0.000 claims 1
- 206010037742 Rabies Diseases 0.000 claims 1
- 208000000705 Rift Valley Fever Diseases 0.000 claims 1
- 206010067470 Rotavirus infection Diseases 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 206010039438 Salmonella Infections Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 208000011312 Vector Borne disease Diseases 0.000 claims 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims 1
- 208000028227 Viral hemorrhagic fever Diseases 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 201000006449 West Nile encephalitis Diseases 0.000 claims 1
- 206010057293 West Nile viral infection Diseases 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 201000008167 cystoisosporiasis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000000292 ehrlichiosis Diseases 0.000 claims 1
- 206010014881 enterobiasis Diseases 0.000 claims 1
- 208000020612 escherichia coli infection Diseases 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 201000005648 hantavirus pulmonary syndrome Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000029080 human African trypanosomiasis Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- -1 lyoprotector Substances 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000003692 opisthorchiasis Diseases 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039447 salmonellosis Diseases 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 201000002612 sleeping sickness Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 208000016808 vibrio vulnificus infectious disease Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 206010061802 Cyclosporidium infection Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 208000015669 capillary disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
Abstract
1. Применение пептида Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 или его солей, гидратов или деацетилированной формы для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 2. Применение пептида по п.1, где инфекционное заболевание представляет собой бактериальное, грибковое или вирусное инфекционное заболевание, которое выбрано из альвеолярного гидатидного заболевания (AHD, эхинококкоза), амебиаза (инфекции Entamoeba histolyca), инвазии Angiostrongylus, анизакиаза, сибирской язвы, бабезиоза (инфекции Babesia), инфекции Balantidum (балантидиаз), инфекции Blastocystis hominis (бластомикоза), боррелиоза, ботулизма, диареи Брайнерда, бруцеллеза, капилляриоза (инвазии Capillaria), синдрома хронической усталости (CFS), болезни Шагаса (американский трипаносомоз), ветряной оспы (вируса ветряной оспы), инфекции Chlamydia pneumoniae, холеры, болезни Крейтцфельда-Якоба (CJD), клонорхоза (инвазия Clonorchis), кожных мигрирующих личинок (CLM) (нематодной инвазии), кокцидиоидомикоза, инфекции вирусом Коксаки А16 (болезни рук, ног и рта), криптококкоза, инфекции Cryptosporidium (криптоспоридиоза), инфекции Culex mosquito (переносчика вируса лихорадки Западного Нила), циклоспориаза (инфекции Cyclospora), цистицеркоза (нейроцистицеркоза), денге/лихорадки денге, инвазии Dipylidium (ленточный червь блох собак и кошек), вируса геморрагической лихорадки Эбола, энцефалита, инфекции Entamoeba coli, инфекции Entamoeba dispar, инфекции Entamoeba hartmanni, инфекции Entamoeba histolytica (амебиаза), инфекции Entamoeba polecki, энтероб
Claims (9)
1. Применение пептида Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 или его солей, гидратов или деацетилированной формы для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ.
2. Применение пептида по п.1, где инфекционное заболевание представляет собой бактериальное, грибковое или вирусное инфекционное заболевание, которое выбрано из альвеолярного гидатидного заболевания (AHD, эхинококкоза), амебиаза (инфекции Entamoeba histolyca), инвазии Angiostrongylus, анизакиаза, сибирской язвы, бабезиоза (инфекции Babesia), инфекции Balantidum (балантидиаз), инфекции Blastocystis hominis (бластомикоза), боррелиоза, ботулизма, диареи Брайнерда, бруцеллеза, капилляриоза (инвазии Capillaria), синдрома хронической усталости (CFS), болезни Шагаса (американский трипаносомоз), ветряной оспы (вируса ветряной оспы), инфекции Chlamydia pneumoniae, холеры, болезни Крейтцфельда-Якоба (CJD), клонорхоза (инвазия Clonorchis), кожных мигрирующих личинок (CLM) (нематодной инвазии), кокцидиоидомикоза, инфекции вирусом Коксаки А16 (болезни рук, ног и рта), криптококкоза, инфекции Cryptosporidium (криптоспоридиоза), инфекции Culex mosquito (переносчика вируса лихорадки Западного Нила), циклоспориаза (инфекции Cyclospora), цистицеркоза (нейроцистицеркоза), денге/лихорадки денге, инвазии Dipylidium (ленточный червь блох собак и кошек), вируса геморрагической лихорадки Эбола, энцефалита, инфекции Entamoeba coli, инфекции Entamoeba dispar, инфекции Entamoeba hartmanni, инфекции Entamoeba histolytica (амебиаза), инфекции Entamoeba polecki, энтеробиоза (заражение острицами), инфекции энтеровирусом (неполиовирусом), инфекции вирусом Эпштейна-Барр, инфекции Escherichia coli, пищевой инфекции, ящура, грибкового дерматита, гастроэнтерита, болезни Хансена (лепры), хантавирусного легочного синдрома, инвазии головными вшами (педикулеза), инфекции Helicobacter pylori, гематологического заболевания, инфекции вирусом Hendra, гепатита (HCV, HBV), опоясывающего герпеса (опоясывающий лишай), эрлихиоза человека, инфекции вирусом парагриппа человека, гриппа, изоспороза (инфекции Isospora), лихорадки Ласса, лейшманиоза, кала-азар (кала-азар, инфекции Leischmania)), вшей (платяные вшей, головные вшей, лобковые вшей), болезни Лайма, малярии, марбургской геморрагической лихорадки, кори, менингита, передающихся комарами заболеваний, инфекции Naegleria, нозокомиальных инфекций, инфекций непатогенными кишечными амебами, онхоцеркоза (речная слепота), описторхоза (инфекции Opistorcis), паровирусной инфекции, чумы, пневмоцистной пневмонии (РСР), полиомиелита, ку-лихорадки, бешенства, инфекции респираторно-синцитиальным вирусом (RSV), ревматической лихорадки, лихорадки Рифт-Валли, речной слепоты (онхоцеркоза), ротавирусной инфекции, инвазии круглыми червями, сальмонеллеза, инфекции Salmonella enteritidis, чесотки, шигеллеза, опоясывающего лишая, сонной болезни, натуральной оспы, инвазии ленточными червями (инвазия цепнями), столбняка, токсического шока, язв (язвенной болезни), кокцидиоза, инфекции Vibrio parahaemolyticus, инфекции Vibrio vulnificus, вирусной геморрагической лихорадки, папиллом, передаваемых через воду инфекционных заболеваний, инфекции вирусом Западного Нила (энцефалита Западного Нила), коклюша или желтой лихорадки.
3. Применение пептида по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
4. Применение пептида по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава.
5. Фармацевтическая композиция, содержащая пептид Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 и/или его деацетилированную форму, по меньшей мере, совместно с одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
6. Фармацевтическая композиция по п.5 в форме лиофилизата или жидкого буферного раствора.
7. Фармацевтическая композиция по п.5 или 6 пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
8. Фармацевтическая композиция по п.5 или 6 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
9. Фармацевтическая композиция по п.5 или 6 пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезней обмена веществ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPEP07017764.7 | 2007-09-11 | ||
| EP07017764 | 2007-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010113968A true RU2010113968A (ru) | 2011-10-20 |
Family
ID=40090324
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010113968/15A RU2010113968A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
| RU2010114048/15A RU2010114048A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида дефензина в качестве терапевтического средства |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010114048/15A RU2010114048A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида дефензина в качестве терапевтического средства |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20100204136A1 (ru) |
| EP (2) | EP2190457A1 (ru) |
| JP (2) | JP2010539042A (ru) |
| KR (2) | KR20100061486A (ru) |
| AU (2) | AU2008310059A1 (ru) |
| CA (2) | CA2704726A1 (ru) |
| RU (2) | RU2010113968A (ru) |
| WO (4) | WO2009043507A2 (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2816868C2 (ru) * | 2018-03-29 | 2024-04-08 | С.И.С Шулов Инновейтив Сайенс Лтд. | Фармацевтические композиции для ингибирования воспалительных цитокинов |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2320929B1 (en) * | 2008-07-18 | 2019-05-29 | Defensin Therapeutics ApS | Human beta defensins for use in the treatment of inflammatory diseases |
| CA2730789A1 (en) | 2008-07-18 | 2010-01-21 | Novozymes Adenium Biotech A/S | Treatment of inflammatory bowel diseases with mammal beta defensins |
| MX2011000567A (es) | 2008-07-18 | 2011-02-23 | Novozymes Adenium Biotech As | Tratamiento de artritis reumatoide con beta-defensinas de mamifero. |
| WO2013007596A2 (en) | 2011-07-08 | 2013-01-17 | Novozymes A/S | Oral treatment of inflammatory bowel disease |
| US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
| US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
| US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
| US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| WO2018201002A1 (en) * | 2017-04-28 | 2018-11-01 | The Schepens Eye Research Institute, Inc. | Methods and compositions for reducing corneal endothelial cell loss |
| KR102146555B1 (ko) * | 2018-11-27 | 2020-08-20 | 국방과학연구소 | 탄저균 특이적 항균능을 갖는 약학적 조성물 및 이의 제조방법 |
| KR102192471B1 (ko) * | 2019-10-18 | 2020-12-17 | 주식회사 인코스팜 | 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US447471A (en) | 1891-03-03 | John f | ||
| US4100271A (en) | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4235988A (en) | 1976-12-13 | 1980-11-25 | Imperial Chemical Industries Limited | Delivery means for biologically active agents |
| US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4474753A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
| US4705777A (en) * | 1985-02-25 | 1987-11-10 | The Regents Of The University Of California | Cationic oligopeptides having microbicidal activity |
| JPS61243025A (ja) * | 1985-02-25 | 1986-10-29 | ザ リ−ジエンツ オブ ザ ユニバ−シテイ オブ カリフオルニア | 殺菌性ペプチド |
| WO1988000833A2 (en) * | 1986-08-08 | 1988-02-11 | Board Of Regents, The University Of Texas System | Antipyretic and anti-inflammatory peptides |
| GB8720115D0 (en) * | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
| IL101441A (en) * | 1992-04-01 | 1999-07-14 | Univ Ramot | Pharmaceutical preparations for the treatment and prevention of diseases or irregularities in the eye |
| FR2719316B1 (fr) * | 1994-04-28 | 1996-05-31 | Idm | Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules. |
| US5837247A (en) * | 1995-06-16 | 1998-11-17 | United States Of America As Represented By The Public Health Service National Institutes Of Health | Chemotactic agents for t-cells |
| US5916582A (en) * | 1996-07-03 | 1999-06-29 | Alza Corporation | Aqueous formulations of peptides |
| US6140315A (en) * | 1997-06-09 | 2000-10-31 | Weisman; Kenneth M. | Therapeutic uses of goserelin acetate |
| US6338834B1 (en) * | 1998-04-30 | 2002-01-15 | The Curators Of The University Of Missouri | Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma |
| PT1191939E (pt) * | 1999-03-24 | 2008-01-04 | Zengen Inc | Sequências de aminoácidos antimicrobianas derivadas da hormona estimulante dos alfa-melanócitos |
| CA2309395A1 (en) * | 1999-06-04 | 2000-12-04 | Richard Lloyd Bowen | Methods for preventing and treating alzheimer's disease |
| US7112566B1 (en) * | 1999-09-17 | 2006-09-26 | The Regents Of The University Of California | Systemic administration of Hypocretin-1 |
| AU2001254625B2 (en) * | 2000-05-02 | 2006-02-02 | Action Pharma A/S | Use of alpha-MSH and EPO for preventing or treating ischemic conditions |
| WO2002030451A1 (en) * | 2000-10-10 | 2002-04-18 | Atossa Healthcare, Inc. | Compositions and methods for reducing gnrh-induced bone loss |
| US20060088512A1 (en) * | 2001-10-15 | 2006-04-27 | Monash University | Treatment of T cell disorders |
| US6780838B2 (en) * | 2001-01-29 | 2004-08-24 | Zengen, Inc. | Compounds for treating fungal pathologies of the oral cavity |
| US6872705B2 (en) * | 2001-07-13 | 2005-03-29 | Allergan, Inc. | Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions |
| US7115574B2 (en) * | 2001-12-10 | 2006-10-03 | Zengen, Inc. | System and method for support legacy operating system booting in a legacy-free system |
| US6939846B2 (en) * | 2001-12-17 | 2005-09-06 | Zengen, Inc. | Use of a polypeptide for treatment of pruritis in animals |
| US20040009181A1 (en) * | 2002-05-21 | 2004-01-15 | Lipton James M. | Treatment of ophthalmic conditions |
| AU2003231947A1 (en) * | 2002-05-31 | 2003-12-19 | Aaron Diamond Aids Research Center | Defensins: use as antiviral agents |
| US20040009170A1 (en) * | 2002-07-10 | 2004-01-15 | Stafano Gatti | Alpha-melanocyte stimulating hormone peptides protection in organ transplantation |
| US20040152769A1 (en) * | 2002-11-09 | 2004-08-05 | Ekwuribe Nnochiri Nkem | Modified carbamate-containing prodrugs and methods of synthesizing same |
| WO2004073168A2 (en) * | 2003-02-07 | 2004-08-26 | Warner Bros. Entertainment Inc. | Methods for encoding data in an analog video signal such that it survives resolution conversion |
| US20050048646A1 (en) * | 2003-08-25 | 2005-03-03 | Medinet Co., Ltd. | Method for inducing cytotoxic T lymphocyte |
| US20070275877A1 (en) * | 2003-08-29 | 2007-11-29 | Amylin Pharmaceuticals, Inc. | Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders |
| US7576060B2 (en) * | 2003-11-07 | 2009-08-18 | The Trustees Of The University Of Pennsylvania | Inhibition of adhesion and migration of an endothelial cell to fibronectin by neutrophil alpha-defensins |
| HUP0400405A3 (en) * | 2004-02-10 | 2009-03-30 | Sanofi Synthelabo | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| DE602005012401D1 (en) * | 2004-07-22 | 2009-03-05 | Max Planck Gesellschaft | Alpha-defensine als anthrax-immuntherapeutika |
| CN101076348A (zh) * | 2004-10-08 | 2007-11-21 | 克里纽沃药物有限公司 | 用于在受试者中诱导黑素原生成的组合物和方法 |
| WO2006119388A2 (en) * | 2005-05-03 | 2006-11-09 | Novetide, Ltd. | Methods for the production of peptide having a c-terminal amide |
| WO2007014051A2 (en) * | 2005-07-22 | 2007-02-01 | Amylin Pharmaceuticals, Inc. | Use of amylin and amylin agonists as cardioprotective or myoprotective agents |
| ITMI20052426A1 (it) * | 2005-12-20 | 2007-06-21 | Fond Irccs Istituto Di Ricovero E Cura ... | Uso dell'ormone a-melanocito stimolante e-o suoi derivati o analoghi per la preparazione di composizioni farmaceutiche per il trattamento di patologie fibroproliferative |
| EP1993515B1 (de) | 2006-03-10 | 2009-07-29 | Laboswiss AG | Verfahren zum solubilisieren, dispergieren und stabilisieren von stoffen, nach dem verfahren hergestellte erzeugnisse sowie die verwendung derselben |
-
2008
- 2008-09-09 US US12/677,582 patent/US20100204136A1/en not_active Abandoned
- 2008-09-09 CA CA2704726A patent/CA2704726A1/en not_active Abandoned
- 2008-09-09 CA CA2699163A patent/CA2699163A1/en not_active Abandoned
- 2008-09-09 EP EP08830174A patent/EP2190457A1/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/008038 patent/WO2009043507A2/en active Application Filing
- 2008-09-09 EP EP08802365A patent/EP2187954B1/en not_active Not-in-force
- 2008-09-09 JP JP2010523415A patent/JP2010539042A/ja active Pending
- 2008-09-09 AU AU2008310059A patent/AU2008310059A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007847 patent/WO2009046833A1/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007849 patent/WO2009046835A1/en active Application Filing
- 2008-09-09 RU RU2010113968/15A patent/RU2010113968A/ru not_active Application Discontinuation
- 2008-09-09 US US12/677,588 patent/US20100210537A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005647A patent/KR20100061486A/ko not_active Application Discontinuation
- 2008-09-09 AU AU2008297551A patent/AU2008297551A1/en not_active Abandoned
- 2008-09-09 JP JP2010523421A patent/JP5491396B2/ja not_active Expired - Fee Related
- 2008-09-09 KR KR1020107005650A patent/KR20100071985A/ko not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007923 patent/WO2009033776A1/en active Application Filing
- 2008-09-09 RU RU2010114048/15A patent/RU2010114048A/ru not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2816868C2 (ru) * | 2018-03-29 | 2024-04-08 | С.И.С Шулов Инновейтив Сайенс Лтд. | Фармацевтические композиции для ингибирования воспалительных цитокинов |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100071985A (ko) | 2010-06-29 |
| AU2008297551A1 (en) | 2009-03-19 |
| EP2187954A1 (en) | 2010-05-26 |
| WO2009046833A1 (en) | 2009-04-16 |
| EP2187954B1 (en) | 2012-07-18 |
| WO2009033776A1 (en) | 2009-03-19 |
| JP5491396B2 (ja) | 2014-05-14 |
| AU2008310059A1 (en) | 2009-04-16 |
| JP2010539042A (ja) | 2010-12-16 |
| WO2009046835A1 (en) | 2009-04-16 |
| WO2009043507A3 (en) | 2009-05-22 |
| RU2010114048A (ru) | 2011-10-20 |
| CA2704726A1 (en) | 2009-03-19 |
| US20100210537A1 (en) | 2010-08-19 |
| WO2009043507A2 (en) | 2009-04-09 |
| EP2190457A1 (en) | 2010-06-02 |
| JP2010539048A (ja) | 2010-12-16 |
| KR20100061486A (ko) | 2010-06-07 |
| US20100204136A1 (en) | 2010-08-12 |
| CA2699163A1 (en) | 2009-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010113968A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114053A (ru) | Применение лептина (22-56) в качестве терапевтического средства | |
| ES2283123T3 (es) | Geles de electrolitos para mantener la hidratacion y la rehidratacion. | |
| Lau et al. | Trimethoprim-sulfamethoxazole treatment of Pneumocystis carinii pneumonia in adults | |
| Bennish | Cholera: pathophysiology, clinical features, and treatment | |
| ES2386292T3 (es) | Composición farmacéutica que comprende un agente antitumoral y un agente activo elegido especialmente entre carveol, timol y carvacrol | |
| CN104983740A (zh) | 用于增强生理性能和恢复时间的组合物和方法 | |
| WO2009040068A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009039993A3 (en) | Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection | |
| WO2009040005A9 (en) | Use of the peptide rfmwmr as a therapeutic agent | |
| JPS63500523A (ja) | 低ナトリウム緩下剤および洗浄剤処方 | |
| ES2267591T3 (es) | Combinaciones farmaceuticas que comprenden un antagonista del receptor p2t y melagatran. | |
| GRABOWSKI et al. | Babesiosis transmitted by a transfusion of frozen-thawed blood | |
| CN107106527B (zh) | 用于治疗疾病症状的氨基酸组合物 | |
| WO2009033791A3 (en) | Use of a peptide as a therapeutic agent | |
| CA2565993A1 (en) | Salt of 4-or 5- aminosalicylic acid | |
| Kramer et al. | Oral and enteral resuscitation of burn shock the historical record and implications for mass casualty care | |
| RU2010113988A (ru) | Применение пептида в качестве терапевтического средства | |
| Stommel et al. | Marine neurotoxins: ingestible toxins | |
| US20040076687A1 (en) | Nutritional supplement containing sea water minerals | |
| US20100151044A1 (en) | Use of isoosmotic seawater-based ionic solutions for manufacturing medical devices for the prevention of complications of the common cold or of the flu syndrome | |
| WO2002100193A1 (en) | Body temperature-raising agent of amino acids for eating or drinking and for medical use | |
| CN113995744A (zh) | 一种组合物及其抗菌应用 | |
| CN101780270A (zh) | 用于治疗禽呼吸道疾病的复方可溶性粉 | |
| Rolston et al. | Jejunal and Heal Glucose-Stimulated Water and Sodium Absorption in Tropical Enteropathy: Implications for Oral Rehydration Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110912 |